Approval of Generic Abacavir Tablets, 300 mg
June 20, 2012
On June 18, 2012, FDA granted approval for a generic formulation of abacavir tablets, 300 mg, manufactured by Mylan Pharmaceuticals, indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
FDA has determined that the generic formulation is bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, ZiagenTablets, a product of VIIV Healthcare Company.
Approval of this generic formulation means that it may be marketed in the United States.
A complete list of approved generic formulations of antiretroviral drugs used in the treatment of HIV infection is available on the FDA web site.
This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)